All In Biotech

Drug Trial Radar · NCT00492037

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

83

Actual

Start

Jan 2000

Primary completion

Not stated

Study completion Feb 2002

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Parke-Davis
First posted
Jun 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of efficacy \& safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia

Conditions

  • Hyponatremia

Interventions

  • YM087 oralDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in serum sodium from Baseline Safety of each dosing regimenTime frame: Beginning through end of treatment

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Brussels, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Tournai, Belgium

  • Site not named

    Jyväskylä, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Garches, France

  • Site not named

    Limoges, France

  • Site not named

    Paris, France

  • Site not named

    Bad Nauheim, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Dresdan, Germany

  • Site not named

    Göttingen, Germany

  • Site not named

    München, Germany

  • Site not named

    Ferrara, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Pisa, Italy

  • Site not named

    Verona, Italy

  • Site not named

    Delft, Netherlands

  • Site not named

    Groningen, Netherlands

  • Site not named

    Leiden, Netherlands

  • Site not named

    Nijmegen, Netherlands

  • Site not named

    Radomsko, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Barcelona, Spain

  • Site not named

    Córdoba, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Cardiff, United Kingdom

  • Site not named

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.